Yr Athro Colin Dayan

(e/fe)

BSc, MBChB, PhD, FRCP

2024

• Martino, M., Galderisi, A., Evans-Molina, C. and Dayan, C. 2024. Revisiting the pattern of loss of β-cell function in preclinical Type 1 Diabetes. Diabetes 73(11), pp. 1769-1779., article number: db240163. (10.2337/db24-0163)
• Scudder, C. et al. 2024. General population screening for type 1 diabetes using islet autoantibodies at the preschool vaccination visit: a proof-of-concept study (the T1Early study). Archives of Disease in Childhood 109, pp. 812-817. (10.1136/archdischild-2023-326697)
• Tatovic, D. et al. 2024. Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial. Nature Medicine 30, pp. 2657-2666. (10.1038/s41591-024-03115-2)
• Heald, A. H. et al. 2024. Liothyronine (LT3) prescribing in England: Are cost constraints inhibiting guideline implementation?. Clinical Endocrinology 101(1), pp. 62-68. (10.1111/cen.15061)
• Scholz, A. et al. 2024. Controlled antenatal thyroid screening study III: Effects of gestational thyroid status on adolescent brain morphology. The Journal of Clinical Endocrinology & Metabolism (10.1210/clinem/dgae338)
• Heald, A. H., Taylor, P., Premawardhana, L., Stedman, M. and Dayan, C. 2024. Natural desiccated thyroid for the treatment of hypothyroidism?. Frontiers in Endocrinology 14, article number: 1309159. (10.3389/fendo.2023.1309159)
• Allen, L. et al. 2024. A study of relative maternal protection against type 1 diabetes in offspring: Statistical analysis plan. Elsevier.
• Wych, J. et al. 2024. Investigating the effect of verapamil on preservation of beta-cell function in adults with newly diagnosed type 1 diabetes mellitus (Ver-A-T1D): protocol for a randomized, double-blind, placebo-controlled, parallel-group, multi-centre trial. BMJ Open

2023

• Galderisi, A., Carr, A. L. J., Martino, M., Taylor, P., Senior, P. and Dayan, C. 2023. Quantifying beta cell function in the preclinical stages of type 1 diabetes. Diabetologia 66, pp. 2189-2199. (10.1007/s00125-023-06011-5)
• Heald, A., Stedman, M., Okosieme, B., Premawardhana, L., Taylor, P. and Dayan, C. 2023. Liothyronine prescribing in England: Costs versus need. The Lancet 402(10417), pp. 2074-2075. (10.1016/S0140-6736(23)01792-0)
• Premawardhana, L. D., Taylor, P. N., Okosieme, O. E., Adlan, M. A., Obuobie, E. K. and Dayan, C. M. 2023. Designing a combined Liothyronine (LT3), L-thyroxine (LT4) trial in symptomatic hypothyroid subjects on LT4 – the importance of patient selection, choice of LT3 and trial design. Frontiers in Endocrinology 14, article number: 1282608. (10.3389/fendo.2023.1282608)
• Taylor, P. N. et al. 2023. C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis. The Lancet Diabetes & Endocrinology 11(12), pp. 915-925. (10.1016/S2213-8587(23)00267-X)
• Taylor, P. et al. 2023. Factors predicting long-term outcome and the need for surgery in Graves orbitopathy: Extended follow-up from the CIRTED trial. The Journal of Clinical Endocrinology & Metabolism 108(10), pp. 2615-2625. (10.1210/clinem/dgad084)
• Allen, L. A., Taylor, P. N., Gillespie, K. M., Oram, R. A. and Dayan, C. M. 2023. Maternal type 1 diabetes and relative protection against offspring transmission. Lancet Diabetes and Endocrinology 11(10), pp. 755-767. (10.1016/S2213-8587(23)00190-0)
• Hanna, S. J. et al. 2023. Single-cell RNAseq identifies clonally expanded antigen-specific T-cells following intradermal injection of gold nanoparticles loaded with diabetes autoantigen in humans. Frontiers in Immunology 14, article number: 1276255. (10.3389/fimmu.2023.1276255)
• Okosieme, O. et al. 2023. Cardiovascular morbidity and mortality in patients in Wales, UK with resistance to thyroid hormone β (RTHβ): a linked-record cohort study. The Lancet Diabetes & Endocrinology 11(9), pp. 657-666. (10.1016/S2213-8587(23)00155-9)
• Ahluwalia, R. et al. 2023. Use of liothyronine (T3) in hypothyroidism: Joint British Thyroid Association/Society for endocrinology consensus statement. Clinical Endocrinology 99(2), pp. 206-216. (10.1111/cen.14935)
• Cantley, J., Eizirik, D., Latres, E. and Dayan, C. 2023. Islet cells in human type 1 diabetes: from recent advances to novel therapies ? a symposium-based roadmap for future research. Journal of Endocrinology 259(1), article number: e230082. (10.1530/JOE-23-0082)
• Mulder, T. A. et al. 2023. Genetic determinants of thyroid function in children. European journal of endocrinology 189(2), pp. 164-174. (10.1093/ejendo/lvad086)
• Holman, N., Woch, E., Dayan, C., Warner, J., Robinson, H., Young, B. and Elliott, J. 2023. National trends in hyperglycemia and diabetic ketoacidosis in children, adolescents, and young adults with type 1 diabetes: a challenge due to age or stage of development, or is new thinking about service provision needed?. Diabetes Care 46(7), pp. 1404–1408. (10.2337/dc23-0180)
• Van Rampelbergh, J. et al. 2023. First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes. BMC Medicine 21(1), article number: 190. (10.1186/s12916-023-02900-z)
• Taylor, P., Lansdown, A., Witczak, J., Khan, R., Rees, A., Dayan, C. and Okosieme, O. 2023. Age-related variation in thyroid function – a narrative review highlighting important implications for research and clinical practice. Thyroid Research 16, article number: 7. (10.1186/s13044-023-00149-5)
• Dayan, C. M. et al. 2023. Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies. Multiple Sclerosis Journal - Experimental, Translational and Clinical 9, article number: 1. (10.1177/20552173221142741)
• Quinn, L. M., Swaby, R., Tatovic, D., Narendran, P., Besser, R. E. J. and Dayan, C. M. 2023. What does the licensing of teplizumab mean for diabetes care?. Diabetes, Obesity and Metabolism (10.1111/dom.15071)
• Tatovic, D., Narendran, P. and Dayan, C. M. 2023. A perspective on treating type 1 diabetes mellitus before insulin is needed. Nature Reviews Endocrinology 19, pp. 361-370. (10.1038/s41574-023-00816-5)
• Thomas, N. J., Hill, A. V., Dayan, C. M., Oram, R. A., McDonald, T. J., Shields, B. M. and Jones, A. G. 2023. Age of diagnosis does not alter the presentation or progression of robustly defined adult-onset type 1 diabetes.. Diabetes Care (10.2337/dc22-2159)

2022

• French, R. et al. 2022. Educational attainment and childhood-onset type 1 diabetes. Diabetes Care 45(12), pp. 2852–2861. (10.2337/dc21-0693)
• Perros, P. et al. 2022. Post-radioiodine Graves' management: the PRAGMA study. Clinical Endocrinology 97(5), pp. 664-675. (10.1111/cen.14719)
• Taylor, P. N. et al. 2022. Prescribing costs of hypoglycaemic agents and associations with metabolic control in Wales; a national analysis of primary care data. Diabetic Medicine 39(9), article number: e14908. (10.1111/dme.14908)
• Tatovic, D. et al. 2022. Diagnosing Type 1 diabetes in adults: Guidance from the UK T1D Immunotherapy consortium. Diabetic Medicine 39(7), article number: e14862. (10.1111/dme.14862)
• Agrawal, M., Lewis, S., Premawardhana, L., Dayan, C. M., Taylor, P. N. and Okosieme, O. E. 2022. Antithyroid drug therapy in pregnancy and risk of congenital anomalies: Systematic review and meta-analysis. Clinical Endocrinology 96(6), pp. 857-868. (10.1111/cen.14646)
• Sims, E. K. et al. 2022. Screening for type 1 diabetes in the general population: a status report and perspective. Diabetes 71(4), pp. 610–623. (10.2337/dbi20-0054)
• Quinn, L. M. et al. 2022. EarLy Surveillance for Autoimmune diabetes: protocol for a qualitative study of general population and stakeholder perspectives on screening for type 1 diabetes in the UK (ELSA 1). BMJ Open Diabetes Research and Care 10(2), article number: e002750. (10.1136/bmjdrc-2021-002750)
• Liang, S. et al. 2022. Relationship between thyroid hormones and metabolic syndrome in a normal thyroid function population in Western China. Chinese Medical Journal 135(3), pp. 350-352. (10.1097/CM9.0000000000001553)
• Tatovic, D. et al. 2022. Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in Type 1 diabetes. Immunotherapy Advances 2(1), article number: ltac002. (10.1093/immadv/ltac002)

2021

• Zhang, L. et al. 2021. The role of mitochondria-linked fatty-acid uptake-driven adipogenesis in Graves’ Orbitopathy. Endocrinology 162(12), article number: bqab188. (10.1210/endocr/bqab188)
• Draman, M. S. et al. 2021. Expression of endogenous putative TSH binding protein in orbit. Current Issues in Molecular Biology 43(3), pp. 1794-1804. (10.3390/cimb43030126)
• Allen, L. A. and Dayan, C. M. 2021. Immunotherapy for type 1 diabetes. British Medical Bulletin 140(1), pp. 76–90. (10.1093/bmb/ldab027)
• Heald, A. H. et al. 2021. Is there a role for natural desiccated thyroid in the treatment of levothyroxine unresponsive hypothyroidism? Results from a consecutive case series. International Journal of Clinical Practice 75(12), article number: e14967. (10.1111/ijcp.14967)
• Bartalena, L. et al. 2021. The 2021 European group on graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of graves’ orbitopathy. European Journal of Endocrinology 185(4), pp. G43-G67. (10.1530/EJE-21-0479)
• Gregory, J. W. et al. 2021. Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): trial protocol. BMJ Open 11(10), article number: e049595. (10.1136/bmjopen-2021-049595)
• Hanna, S. J., Tatovic, D., Thayer, T. C. and Dayan, C. M. 2021. Insights from single cell RNA sequencing Into the immunology of type 1 diabetes- cell phenotypes and antigen specificity. Frontiers in Immunology 12, article number: 751701. (10.3389/fimmu.2021.751701)
• Stedman, M., Taylor, P., Premawardhana, L., Okosieme, O., Dayan, C. and Heald, A. H. 2021. Liothyronine and levothyroxine prescribing in England: A comprehensive survey and evaluation. International Journal of Clinical Practice 75(9), article number: e14228. (10.1111/ijcp.14228)
• Dayan, C. M. et al. 2021. Preventing type 1 diabetes in childhood. Science 373(6554), pp. 506-510. (10.1126/science.abi4742)
• Stedman, M., Taylor, P., Premawardhana, L., Okosieme, O., Dayan, C. and Heald, A. H. 2021. Trends in costs and prescribing for liothyronine and levothyroxine in England and Wales 2011-2020. Clinical Endocrinology 94(6), pp. 980-989. (10.1111/cen.14414)
• Siah, Q. Z., Ubeysekara, N. H., Taylor, P. N., Davies, S. J., Wong, F., Dayan, C. M. and Alhadj Ali, M. 2021. Referral rates of patients with diabetes to secondary care are inversely related to the prevalence of diabetes in each primary care practice and confidence in treatment, not to HbA1c level. Primary Care Diabetes 15(3), pp. 513-517. (10.1016/j.pcd.2021.02.004)
• Singh, R. K. et al. 2021. Using gold nanoparticles for enhanced intradermal delivery of poorly soluble auto-antigenic peptides. Nanomedicine: Nanotechnology, Biology and Medicine 32, article number: 102321. (10.1016/j.nano.2020.102321)
• Jonklaas, J. et al. 2021. Evidence-based use of levothyroxine/liothyronine combinations in treating hypothyroidism: a consensus document. Thyroid Journal Program 31(2), pp. 156-182. (10.1089/thy.2020.0720)
• Lam, A., Dayan, C. and Herold, K. C. 2021. A little help from residual β cells has long-lasting clinical benefits. Journal of Clinical Investigation 131(3), article number: e143683. (10.1172/JCI143683)
• Delles, C., Dayan, C. M., Dominiczak, A. F., Donnelly, S. C. and Irvine, A. D. 2021. Announcing the first AoP webinar: 'Can evidence-based medicine survive in a pandemic'?. QJM: An International Journal of Medicine 114(1), pp. 11-12. (10.1093/qjmed/hcaa287)
• Tatovic, D. and Dayan, C. M. 2021. Replacing insulin with immunotherapy: Time for a paradigm change in Type 1 diabetes. Diabetic Medicine 38, article number: e14696. (10.1111/dme.14696)

2020

• Zhang, L. et al. 2020. Distinctive features of orbital adipose tissue (OAT) in Graves' orbitopathy. International Journal of Molecular Sciences 21(23), article number: 9145. (10.3390/ijms21239145)
• Lee, V., Avari, P., Williams, B., Perros, P. and Dayan, C. 2020. A survey of current practices by the British Oculoplastic Surgery Society (BOPSS) and recommendations for delivering a sustainable multidisciplinary approach to thyroid eye disease in the United Kingdom. Eye 34, pp. 1662-1671. (10.1038/s41433-019-0664-z)
• Muller, I. et al. 2020. CATS II long-term anthropometric and metabolic effects of maternal sub-optimal thyroid function in offspring and mothers. Journal of Clinical Endocrinology and Metabolism 105(7), article number: dgaa129. (10.1210/clinem/dgaa129)
• Hanna, S. J. et al. 2020. Slow progressors to type 1 diabetes lose islet autoantibodies over time, have few islet antigen-specific CD8+ T cells and exhibit a distinct CD95hi B cell phenotype. Diabetologia 63, pp. 1174-1185., article number: Diabetologia volume 63, pages1174–1185(2020). (10.1007/s00125-020-05114-7)
• Arikat, F. et al. 2020. Targeting proinsulin to local immune cells using an intradermal microneedle delivery system; a potential antigen-specific immunotherapy for type 1 diabetes. Journal of Controlled Release 322, pp. 593-601. (10.1016/j.jconrel.2020.02.031)
• Derakhshan, A. et al. 2020. Association of maternal thyroid function with birthweight: a systematic review and individual-participant data meta-analysis. Lancet Diabetes and Endocrinology 8(6), pp. 501-510. (10.1016/S2213-8587(20)30061-9)
• Allen, L. A. et al. 2020. Pregnancy in teenagers diagnosed with type 1 diabetes mellitus in childhood: a national population based e-cohort study. Diabetologia 63, pp. 799-810. (10.1007/s00125-019-05063-w)
• Hales, C. et al. 2020. Controlled antenatal thyroid screening II: Effect of treating maternal sub-optimal thyroid function on child behaviour. Journal of Clinical Endocrinology and Metabolism 105(3), article number: dgz098. (10.1210/clinem/dgz098)
• Okosieme, O. E., Taylor, P. N. and Dayan, C. M. 2020. Should radioiodine now be first line treatment for Graves' disease?. Thyroid Research 13(1), article number: 3. (10.1186/s13044-020-00077-8)
• Oakley, N. J., Kneale, D., Mann, M., Hilliar, M., Dayan, C., Gregory, J. W. and French, R. 2020. Type 1 diabetes mellitus and educational attainment in childhood: a systematic review. BMJ Open 10(1), article number: e033215. (10.1136/bmjopen-2019-033215)

2019

• Taylor, P. N. et al. 2019. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nature Reviews Endocrinology 16(2), pp. 104-116. (10.1038/s41574-019-0305-4)
• Yang, J. H. M. et al. 2019. Phenotypic analysis of human lymph nodes in subjects with new-onset type 1 diabetes and healthy individuals by flow cytometry. Frontiers in Immunology 10, pp. -., article number: 2547. (10.3389/fimmu.2019.02547)
• Taylor, P. N., Eligar, V., Muller, I., Scholz, A., Dayan, C. and Okosieme, O. 2019. Combination thyroid hormone replacement; knowns and unknowns. Frontiers in Endocrinology 10, article number: 706. (10.3389/fendo.2019.00706)
• Dayan, C. M., Korah, M., Tatovic, D., Bundy, B. N. and Herold, K. C. 2019. Changing the landscape for type 1 diabetes: the first step to prevention. Lancet 394(10205), pp. 1286-1296. (10.1016/S0140-6736(19)32127-0)
• Powell, W. et al. 2019. Detecting autoreactive B cells in the peripheral blood of people with type 1 diabetes using ELISpot. Journal of Immunological Methods 471, pp. 61-65. (10.1016/j.jim.2019.05.007)
• Korevaar, T. I. M. et al. 2019. Association of thyroid function test abnormalities and thyroid autoimmunity with preterm birth: a systematic review and meta-analysis. Journal of the American Medical Association 322(7), pp. 632-641. (10.1001/jama.2019.10931)
• Muller, I., Moran, C., Lecumberri, B., Decallonne, B., Robertson, N., Jones, J. and Dayan, C. 2019. 2019 European thyroid association guidelines on the management of thyroid dysfunction following immune reconstitution therapy. European Thyroid Journal 8(4), pp. 173-185. (10.1159/000500881)
• Pearce, S. H. et al. 2019. Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves' hyperthyroidism: a phase I study. Thyroid 29(7), pp. 1003-1011. (10.1089/thy.2019.0036)
• Wilson, N. et al. 2019. Role of hyaluronan in human adipogenesis: Evidence from in-vitro and in-vivo studies. International Journal of Molecular Sciences 20(11), article number: 2675. (10.3390/ijms20112675)
• Dul, M. et al. 2019. Conjugation of a peptide autoantigen to gold nanoparticles for intradermally administered antigen specific immunotherapy. International Journal of Pharmaceutics 562, pp. 303-312. (10.1016/j.ijpharm.2019.03.041)
• Okosieme, O. E. et al. 2019. Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study. Lancet Diabetes and Endocrinology 7(4), pp. 278-287. (10.1016/S2213-8587(19)30059-2)
• Draman, M. S. et al. 2019. Prostaglandin F2-alpha eye drops (bimatoprost) in Graves' orbitopathy: a randomized controlled double-masked crossover trial (BIMA Trial). Thyroid Journal Program 29(4), pp. 563-572. (10.1089/thy.2018.0506)
• Taylor, P. N., Razvi, S., Muller, I., Wass, J., Dayan, C. M., Chatterjee, K. and Boelaert, K. 2019. Liothyronine cost and prescriptions in England. Lancet Diabetes and Endocrinology 7(1), pp. 11-12. (10.1016/S2213-8587(18)30334-6)

2018

• Muller, I. et al. 2018. Longitudinal characterization of autoantibodies to the thyrotropin receptor (TRAb) during alemtuzumab therapy; evidence that TRAb may precede thyroid dysfunction by many years.. Thyroid 28(12), pp. 1682-1693. (10.1089/thy.2018.0232)
• Beltrami, C. et al. 2018. Association of elevated urinary miR-126, miR-155, and miR-29b with diabetic kidney disease. American Journal of Pathology 188(9), pp. 1982-1992. (10.1016/j.ajpath.2018.06.006)
• Powell, W. E. et al. 2018. Loss of CXCR3 expression on memory B cells in individuals with long-standing type 1 diabetes. Diabetologia 61, pp. 1794-1803. (10.1007/s00125-018-4651-x)
• Oakley, N. et al. 2018. The association between Type 1 diabetes mellitus and educational attainment in childhood: a systematic review protocol. BMJ Open 8(8), article number: e021893. (10.1136/bmjopen-2018-021893)
• Pariani, N. et al. 2018. Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features. Journal of Clinical Endocrinology & Metabolism 108(8), pp. 3010-3018. (10.1210/jc.2018-00359)
• Asderakis, A., Khalid, U., Madden, S. and Dayan, C. M. 2018. The influence of socioeconomic deprivation on outcomes in pancreas transplantation in England; Registry Data Analysis. American Journal of Transplantation 18(6), pp. 1380-1387. (10.1111/ajt.14633)
• Peterson, S. J. et al. 2018. An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid 28(6), pp. 707. (10.1089/thy.2017.0681)
• Taylor, P. N., Albrecht, D., Scholz, A., Gutierrez-Buey, G., Lazarus, J. H., Dayan, C. M. and Okosieme, O. E. 2018. Global epidemiology of hyperthyroidism and hypothyroidism. Nature Reviews Endocrinology 14(5), pp. 301-316. (10.1038/nrendo.2018.18)
• Hales, C. et al. 2018. Controlled antenatal thyroid screening II: effect of treating maternal sub-optimal thyroid function on child cognition. Journal of Clinical Endocrinology and Metabolism 103(4), pp. 1583-1591. (10.1210/jc.2017-02378)
• Rajendram, R. et al. 2018. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial. Lancet Diabetes and Endocrinology 6(4), pp. 299-309. (10.1016/S2213-8587(18)30021-4)
• Bravis, V. et al. 2018. Relationship between islet autoantibody status and the clinical characteristics of children and adults with incident type 1 diabetes in a UK cohort. BMJ Open 8(4), article number: e020904. (10.1136/bmjopen-2017-020904)
• Dietrich, A. et al. 2018. Establishing the usefulness of the GO-QOL in a UK hospital-treated population with thyroid eye disease in the CIRTED trial. Psychology, Health and Medicine 23(18), pp. 1341-1355. (10.1080/13548506.2018.1503693)
• Wasag, D. R., Gregory, J. W., Dayan, C. and Harvey, J. R. 2018. Excess all-cause mortality before age 30 in childhood onset type 1 diabetes: data from the Brecon Group Cohort in Wales. Archives of Disease in Childhood 103(1), pp. 44-48. (10.1136/archdischild-2016-312581)
• Dew, R. et al. 2018. Attitudes and perceptions of health professionals towards management of hypothyroidism in general practice: a qualitative interview study. BMJ Open 8(2), article number: e019970. (10.1136/bmjopen-2017-019970)

2017

• Dul, M. et al. 2017. Hydrodynamic gene delivery in human skin using a hollow microneedle device. Journal of Controlled Release 265, pp. 120-131. (10.1016/j.jconrel.2017.02.028)
• Zhao, X., Coulman, S. A., Hanna, S. J., Wong, F. S., Dayan, C. M. and Birchall, J. C. 2017. Formulation of hydrophobic peptides for skin delivery via coated microneedles. Journal of Controlled Release 265, pp. 2-13. (10.1016/j.jconrel.2017.03.015)
• Alhadj Ali, M. et al. 2017. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. Science Translational Medicine 9(402), article number: eaaf7779. (10.1126/scitranslmed.aaf7779)
• Muller, I. et al. 2017. TPOAb and thyroid function are not associated with breast cancer outcome: evidence from a large-scale study using data from the Taxotere as Adjuvant Chemotherapy Trial (TACT, CRUK01/001). European Thyroid Journal 6(4), pp. 197-207. (10.1159/000460246)
• Taylor, P. N. et al. 2017. Maturation in serum thyroid function parameters over childhood and puberty: results of a longitudinal study. Journal of Clinical Endocrinology and Metabolism 102(7), pp. 2508-2515. (10.1210/jc.2016-3605)
• Dew, R. et al. 2017. Patients' attitudes and perceptions towards treatment of hypothyroidism in general practice: an in-depth qualitative interview study. BJGP Open, article number: BJGP-2017-0125. (10.3399/bjgpopen17X100977)
• Draman, M. S., Stechman, M., Scott-Coombes, D., Dayan, C. M., Rees, D. A., Ludgate, M. and Zhang, L. 2017. The role of thyrotropin receptor activation in adipogenesis and modulation of fat phenotype. Frontiers in Endocrinology 8, article number: 83. (10.3389/fendo.2017.00083)
• Alhadj Ali, M., Gee, N., Howell, A., Stenson, R. and Dayan, C. 2017. Factors influencing effective recruitment to phase 1 interventional trials in new-onset type 1 diabetes: analysis of 12 months referrals to diabetes research centre [Abstract]. Diabetic Medicine 34(S1), article number: P122. (10.1111/dme.16_13304)
• Dew, R. et al. 2017. Clinical, behavioural and pharmacogenomic factors influencing the response to levothyroxine therapy in patients with primary hypothyroidism-protocol for a systematic review. Systematic Reviews 6(1), article number: 60. (10.1186/s13643-017-0457-z)
• Mellington, F. E. et al. 2017. Management of thyroid eye disease in the United Kingdom: A multi-centre thyroid eye disease audit. Orbit 36(3), pp. 159-169. (10.1080/01676830.2017.1280057)
• Alhadj Ali, M., Bowen-Morris, J., Gee, N. T., Stenson, R., Walkey, H., Littlemore, K. and Dayan, C. 2017. Use of a “YouTube” style video clip to raise interest amongst young people with new‐onset Type 1 diabetes in immunotherapy trials [Abstract]. Diabetic Medicine 34(S1), article number: P315. (10.1111/dme.24_13304)
• Arif, S. et al. 2017. β-cell specific T-lymphocyte response has a distinct inflammatory phenotype in children with Type 1 diabetes compared with adults. Diabetic Medicine 34(3), pp. 419-425. (10.1111/dme.13153)

2016

• Korevaar, T. I., Taylor, P., Dayan, C. and Peeters, R. P. 2016. An Invitation to Join the Consortium on Thyroid and Pregnancy [Letter]. European Thyroid Journal 5(4), pp. 277. (10.1159/000452331)
• Korevaar, T. I. M., Taylor, P. N., Dayan, C. M. and Peeters, R. P. 2016. An invitation to join the consortium on thyroid and pregnancy. Obstetrics and Gynaecology 128(4), pp. 913. (10.1097/AOG.0000000000001670)
• Tatovic, D., Luzio, S., Dunseath, G., Liu, Y., Alhadj Ali, M., Peakman, M. and Dayan, C. M. 2016. Stimulated urine C-peptide creatinine ratio vs serum C-peptide level for monitoring of β-cell function in the first year after diagnosis of Type 1 diabetes. Diabetic Medicine 33(11), pp. 1564-1568. (10.1111/dme.13186)
• Eligar, V., Taylor, P. N., Okosieme, O., Leese, G. and Dayan, C. M. 2016. Thyroxine replacement: a clinical endocrinologists viewpoint. Annals of Clinical Biochemistry 53(4), pp. 421-433. (10.1177/0004563216642255)
• Vedhara, K. et al. 2016. Illness beliefs predict mortality in patients with diabetic foot ulcers. PLoS ONE 11(4), pp. e0153315. (10.1371/journal.pone.0153315)
• Bartalena, L. et al. 2016. The 2016 European Thyroid Association/European Group on Graves' Orbitopathy guidelines for the management of Graves' Orbitopathy. European Thyroid Journal 5(1), pp. 9-26. (10.1159/000443828)
• Muller, I., Zhang, L., Giani, C., Dayan, C. M., Ludgate, M. E. and Grennan-Jones, F. 2016. The sodium iodide symporter is unlikely to be a thyroid/breast shared antigen. Journal of Endocrinological Investigation 39(3), pp. 323-331. (10.1007/s40618-015-0368-6)
• Alhadj Ali, M. et al. 2016. Assessing fear of hypoglycaemia in newly disgnosed patients with Type 1 diabetes. Diabetic Medicine 33(1), article number: P149. (10.1111/dme.20_13048)
• Zhao, X. et al. 2016. Microneedle delivery of autoantigen for immunotherapy in type 1 diabetes. Journal of Controlled Release 223, pp. 178-187. (10.1016/j.jconrel.2015.12.040)
• Taylor, P. et al. 2016. Paradoxical relationship between body mass index and thyroid hormone levels: a study using Mendelian randomization. Journal of Clinical Endocrinology & Metabolism 101(2), pp. 730-738. (10.1210/jc.2015-3505)
• Okosieme, O. et al. 2016. Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee. Clinical Endocrinology 84(6), pp. 799-808. (10.1111/cen.12824)

2015

• Alhadj Ali, M. et al. 2015. Topical steroid therapy induces pro-tolerogenic changes in Langerhans cells in human skin. Immunology 146(3), pp. 411-422. (10.1111/imm.12518)
• Perros, P. et al. 2015. Future research in Graves' Orbitopathy: from priority setting to trial design through patient and public involvement. Thyroid: official journal of the American Thyroid Association 25(11), pp. 1181-1184. (10.1089/thy.2015.0222)
• Zhang, L. et al. 2015. Reversal of pathological features of Graves' orbitopathy by activation of forkhead transcription factors, FOXOs. Journal of Clinical Endocrinology & Metabolism 101(1), pp. 114-122. (10.1210/jc.2015-2932)
• Perros, P. et al. 2015. PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. British Journal of Ophthalmology 99(11), pp. 1531-1535. (10.1136/bjophthalmol-2015-306733)
• Dunseath, G. et al. 2015. Bridging-type enzyme-linked immunoassay for zinc transporter 8 autoantibody measurements in adult patients with diabetes mellitus. Clinica Chimica Acta 447, pp. 90-95. (10.1016/j.cca.2015.05.010)
• Tatovic, D., Young, P., Kochba, E., Levin, Y., Wong, F. S. and Dayan, C. M. 2015. Fine-needle aspiration biopsy of the lymph node: a novel tool for the monitoring of immune responses after skin antigen delivery. Journal of Immunology 195(1), pp. 386-392. (10.4049/jimmunol.1500364)
• Wolfe, A. et al. 2015. Bariatric surgery in morbidly obese insulin resistant humans normalises insulin signalling but not insulin-stimulated glucose disposal. PLoS ONE 10(4), pp. 1-10., article number: e0120084. (10.1371/journal.pone.0120084)
• Sayers, A. et al. 2015. Evidence for a persistent, major excess in all cause admissions to hospital in children with type-1 diabetes: results from a large Welsh national matched community cohort study. BMJ Open 5, article number: e005644. (10.1136/bmjopen-2014-005644)
• Perros, P. et al. 2015. Management of patients with Graves' orbitopathy: initial assessment, management outside specialised centres and referral pathways. Clinical Medicine 15(2), pp. 173-178. (10.7861/clinmedicine.15-2-173)
• Dhanda, A. D. et al. 2015. Long-term outcome in patients with severe alcoholic hepatitis can be reliably determined using anin vitromeasure of steroid sensitivity. Hepatology 61(3), pp. 1099. (10.1002/hep.27211)
• Skowera, A. et al. 2015. β-Cell-specific CD8 T Cell phenotype in Type 1 diabetes reflects chronic autoantigen exposure. Diabetes 64(3), pp. 916-925. (10.2337/db14-0332)
• Mitchell, A. L. et al. 2015. Diagnosis of Graves' orbitopathy (DiaGO): results of a pilot study to assess the utility of an office tool for practicing endocrinologists. Journal of Clinical Endocrinology & Metabolism 100(3), pp. E458-E462. (10.1210/jc.2014-3146)

2014

• Taylor, P. N. et al. 2014. Maternal perchlorate levels in women with borderline thyroid function during pregnancy and the cognitive development of their offspring: data from the controlled antenatal thyroid study. Journal of Clinical Endocrinology and Metabolism 99(11), pp. 4291-4298. (10.1210/jc.2014-1901)
• Vedhara, K. et al. 2014. Illness beliefs predict self-care behaviours in patients with diabetic foot ulcers: A prospective study. Diabetes Research and Clinical Practice 106(1), pp. 67-72. (10.1016/j.diabres.2014.07.018)
• Taylor, P. et al. 2014. TSH levels and risk of miscarriage in women on long-term levothyroxine: a community-based study. Journal of Clinical Endocrinology & Metabolism 99(10), pp. 3895-3902. (10.1210/jc.2014-1954)
• Zhang, L. et al. 2014. Possible targets for nonimmunosuppressive therapy of Graves' orbitopathy. Journal of Clinical Endocrinology & Metabolism 99(7), pp. E1183-E1190. (10.1210/jc.2013-4182)
• Muller, I. et al. 2014. Does thyroid peroxidase provide an antigenic link between thyroid autoimmunity and breast cancer?. International Journal of Cancer 134(7), pp. 1706-1714. (10.1002/ijc.28493)
• Taylor, P. N. et al. 2014. Falling threshold for treatment of borderline elevated thyrotropin levels - balancing benefits and risks: evidence from a large community-based study. JAMA Internal Medicine 174(1), pp. 32-39. (10.1001/jamainternmed.2013.11312)
• Taylor, P., Okosieme, O., Dayan, C. and Lazarus, J. 2014. Therapy of endocrine disease: impact of iodine supplementation in mild-to-moderate iodine deficiency: systematic review and meta-analysis. European Journal of Endocrinology 170(1), pp. R1-R15. (10.1530/EJE-13-0651)
• Hales, C. et al. 2014. The second wave of the Controlled Antenatal Thyroid Screening (CATS II) study: the cognitive assessment protocol. BMC Endocrine Disorders 14(1), article number: 95. (10.1186/1472-6823-14-95)

2013

• Draman, M. et al. 2013. Effects of Prostaglandin F2a on adipocyte biology relevant to graves' orbitopathy. Thyroid: official journal of the American Thyroid Association 23(12), pp. 1600-1608. (10.1089/thy.2013.0194)
• Taylor, P., Razvi, S., Pearce, S. H. and Dayan, C. 2013. A review of the clinical consequences of variation in thyroid function within the reference range. Journal of Clinical Endocrinology & Metabolism 98(9), pp. 3562-3571. (10.1210/jc.2013-1315)
• Liu, Y., Peakman, M. and Dayan, C. M. 2013. Safely targeting autoimmunity in type 1 diabetes: the MonoPepT1De trial. Practical Diabetes 30(4), pp. 148-150a. (10.1002/pdi.1764)
• Tatovic, D., Pearton, M., Birchall, J. C., Wong, S. and Dayan, C. M. 2013. Topical steroid has the potential of modulating skin dendritic cells to tolerogenic antigen presenting cells in human organ skin bath culture [Abstract]. Diabetic Medicine 30(s1), pp. 53-53. (10.1111/dme.12091_1)
• Waheed, N., Butt, M. and Dayan, C. M. 2013. Hypoglycaemia documented with real-time continuous glucose sensing in a case of 'dead in bed' syndrome. Practical Diabetes 30(1), pp. 33-35. (10.1002/pdi.1737)

2012

• Raghavan, R. P. et al. 2012. Amiodarone-induced thyrotoxicosis, an overview of UK management [Letter]. Clinical Endocrinology 77(6), pp. 936-937. (10.1111/j.1365-2265.2012.04435.x)
• Alhadj Ali, M., Hanna, S., Wong, S. and Dayan, C. 2012. Functional modulation of epidermal dendritic cells by topical steroid treatment to optimise the tolerogenic potential of immunotherapy for type 1 diabetes [Abstract]. Diabetologia 55(S1), pp. S192. (10.1007/s00125-012-2688-9)
• Sands, B. E. et al. 2012. Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis. Gastroenterology 143(2), pp. 356-364. (10.1053/j.gastro.2012.04.043)
• Kronenberg, D. et al. 2012. Circulating preproinsulin signal peptide-specific CD8 T cells restricted by the susceptibility molecule HLA-A24 are expanded at onset of type 1 diabetes and kill β-cells. Diabetes 61(7), pp. 1752-1759. (10.2337/db11-1520)
• Vedhara, K. et al. 2012. Development and preliminary evaluation of a psychosocial intervention for modifying psychosocial risk factors associated with foot re-ulceration in diabetes. Behaviour Research and Therapy 50(5), pp. 323-332. (10.1016/j.brat.2012.02.013)
• Zhang, L., Grennan-Jones, F. A., Lane, C., Rees, D. A., Dayan, C. M. and Ludgate, M. E. 2012. Adipose tissue depot-specific differences in the regulation of hyaluronan production of relevance to Graves' orbitopathy. Journal of Clinical Endocrinology & Metabolism 97(2), pp. 653-662. (10.1210/jc.2011-1299)
• Dawson, C., Dhanda, A., Conway-Campbell, B., DiMambro, A., Lightman, S. and Dayan, C. M. 2012. NFκB and glucocorticoid receptor activity in steroid resistance. Journal of Receptors and Signal Transduction 32(1), pp. 29-35. (10.3109/10799893.2011.641977)
• Perros, P. et al. 2012. Orbital decompression for Graves' orbitopathy in England. Eye 26(3), pp. 434-437. (10.1038/eye.2011.323)

2011

• Rajendram, R., Bunce, C., Adams, G. G. W., Dayan, C. M. and Rose, G. E. 2011. Smoking and strabismus surgery in patients with thyroid eye disease. Ophthalmology 118(12), pp. 2493-2497. (10.1016/j.ophtha.2011.06.003)
• Alhadj Ali, M., Thrower, S., Harris, S., Wong, S. and Dayan, C. 2011. Optimizing the tolerogenic potential of a 'vaccine' for type 1 diabetes by topical betamethasone therapy [Abstract]. Diabetologia 54(S1), pp. S88-S89. (10.1007/s00125-011-2276-4)
• Arif, S. et al. 2011. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated β-cell death. Diabetes 60(8), pp. 2112-2119. (10.2337/db10-1643)
• Andrews, R. C. et al. 2011. Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes: The Early ACTID randomised controlled trial. The Lancet 378(9786), pp. 129-139. (10.1016/S0140-6736(11)60442-X)
• Taylor, P. N. et al. 2011. A meta-analysis of the associations between common variation in the PDE8B gene and thyroid hormone parameters, including assessment of longitudinal stability of associations over time and effect of thyroid hormone replacement. European Journal of Endocrinology 164(5), pp. 773-780. (10.1530/EJE-10-0938)
• Alhadj Ali, M., Thrower, S., Harris, S., Wong, S. and Dayan, C. 2011. Effects of topical steroid and vitamin D therapy in optimizing the tolerogenic potential of a 'vaccine' for type 1 diabetes. Diabetic Medicine 28(S1), pp. 80. (10.1111/j.1464-5491.2011.03233_1.x)
• Mallone, R. et al. 2011. Immunology of diabetes society T-Cell workshop: HLA class I tetramer-directed epitope validation initiative T-Cell workshop report-HLA class I tetramer validation initiative. Diabetes/Metabolism Research and Reviews 27(8), pp. 720-726. (10.1002/dmrr.1243)
• di Mambro, A. J., Parker, R., McCune, C. A., Gordon, F., Dayan, C. M. and Collins, P. W. 2011. In vitro steroid resistance correlates with outcome in severe alcoholic hepatitis. Hepatology 53(4), pp. 1316-1322. (10.1002/hep.24159)
• Cooper, A. R. et al. 2011. Sedentary time, breaks in sedentary time and metabolic variables in people with newly diagnosed type 2 diabetes. Diabetologia 55(3), pp. 589-599. (10.1007/s00125-011-2408-x)
• Walsh, J. P. et al. 2011. The clinical presentation of autoimmune thyroid disease in men is associated with IL12B genotype. Clinical Endocrinology 74(4), pp. 508-512. (10.1111/j.1365-2265.2010.03970.x)
• Hermanides, J. et al. 2011. Sensor-augmented pump therapy lowers HbA1c in suboptimally controlled Type-1 diabetes; a randomized controlled trial. Diabetic Medicine 28(10), pp. 1158-1167. (10.1111/j.1464-5491.2011.03256.x)
• Bould, H., Panicker, V., Kessler, D., Durant, C., Lewis, G., Dayan, C. M. and Evans, J. 2011. Investigation of thyroid dysfunction is more likely in patients with high psychological morbidity. Family Practice 29(2), pp. 163-167. (10.1093/fampra/cmr059)

2010

• Vedhara, K. et al. 2010. Coping style and depression influence the healing of diabetic foot ulcers: observational and mechanistic evidence. Diabetologia 53(8), pp. 1590-1598. (10.1007/s00125-010-1743-7)
• Petrich de Marquesini, L. G. et al. 2010. IFN-γ and IL-10 islet-antigen-specific T cell responses in autoantibody-negative first-degree relatives of patients with type 1 diabetes. Diabetologia 53(7), pp. 1451-1460. (10.1007/s00125-010-1739-3)
• Rees, D. A. and Dayan, C. M. 2010. Commentary: Testosterone and the metabolic syndrome: cause or consequence?. International Journal of Epidemiology 40(1), pp. 207-209. (10.1093/ije/dyq254)

2009

• Alhadj Ali, M. and Dayan, C. M. 2009. Review: The importance of residual endogenous beta-cell preservation in type 1 diabetes. British Journal of Diabetes and Vascular Disease 9(6), pp. 248-253. (10.1177/1474651409351881)
• Estcourt, S., Hickey, J., Perros, P., Dayan, C. M. and Vaidya, B. 2009. The patient experience of services for thyroid eye disease in the United Kingdom: results of a nationwide survey. European Journal of Endocrinology 161(3), pp. 483-487. (10.1530/EJE-09-0383)
• Panicker, V., Saravanan, P., Vaidya, B., Evans, J., Hattersley, A. T., Frayling, T. M. and Dayan, C. M. 2009. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. Journal of Clinical Endocrinology & Metabolism 94(5), pp. 1623-1629. (10.1210/jc.2008-1301)
• Allen, J. S. et al. 2009. Plasmacytoid dendritic cells are proportionally expanded at diagnosis of Type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture. Diabetes 58(1), pp. 138-145. (10.2337/db08-0964)
• Thrower, S. L. et al. 2009. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study. Clinical and Experimental Immunology 155(2), pp. 156-165. (10.1111/j.1365-2249.2008.03814.x)
• Williams, M. D., Harris, R., Dayan, C. M., Evans, J., Gallacher, J. E. and Ben-Shlomo, Y. 2009. Thyroid function and the natural history of depression: findings from the Caerphilly Prospective Study (CaPS) and a meta-analysis. Clinical Endocrinology 70(3), pp. 484-492. (10.1111/j.1365-2265.2008.03352.x)
• Panicker, V., Evans, J., Bjøro, T., Åsvold, B. O., Dayan, C. M. and Bjerkeset, O. 2009. A paradoxical difference in relationship between anxiety, depression and thyroid function in subjects on and not on T4: findings from the HUNT study. Clinical Endocrinology 71(4), pp. 574-580. (10.1111/j.1365-2265.2008.03521.x)
• Lee, R. W. J., Schewitz, L. P., Nicholson, L. B., Dayan, C. M. and Dick, A. D. 2009. Steroid refractory CD4+ T Cells in patients with sight-threatening uveitis. Investigative Ophthalmology and Visual Science 50(9), pp. 4273-4278. (10.1167/iovs.08-3152)
• Creed, T. J., Lee, R. W., Newcomb, P. V., di Mambro, A. J., Raju, M. and Dayan, C. M. 2009. The effects of cytokines on suppression of lymphocyte proliferation by dexamethasone. The Journal of Immunology 183(1), pp. 164-171. (10.4049/jimmunol.0801998)
• Dayan, C. M. and Panicker, V. 2009. Novel insights into thyroid hormones from the study of common genetic variation. Nature Reviews Endocrinology 5(4), pp. 211-218. (10.1038/nrendo.2009.19)

2008

• Skowera, A. et al. 2008. CTLs are targeted to kill β cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. Journal of Clinical Investigation 118(10), pp. 3390-3402. (10.1172/JCI35449)
• Panicker, V. et al. 2008. A common variation in deiodinase 1 gene DIO1 is associated with the relative levels of free thyroxine and triiodothyronine. Journal of Clinical Endocrinology & Metabolism 93(8), pp. 3075-3081. (10.1210/jc.2008-0397)
• Melzer, D. et al. 2008. A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genetics 4(5), article number: e1000072. (10.1371/journal.pgen.1000072)
• Baker, C., Petrich de Marquesini, L. G., Bishop, A. J., Hedges, A. J., Dayan, C. M. and Wong, F. S. 2008. Human CD8 responses to a complete epitope set from preproinsulin: implications for approaches to epitope discovery. Journal of Clinical Immunology 28(4), pp. 350-360. (10.1007/s10875-008-9177-4)
• Wong, F. S. and Dayan, C. M. 2008. Regulatory T cells in autoimmune endocrine diseases. Trends in Endocrinology & Metabolism 19(8), pp. 292-299. (10.1016/j.tem.2008.07.007)
• Dayan, C. M. and Wraith, D. C. 2008. Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412. Clinical and Experimental Immunology 151(2), pp. 231-234. (10.1111/j.1365-2249.2007.03559.x)
• Lawson, J. M., Tremble, J., Dayan, C. M., Beyan, H., Leslie, R. D. G., Peakman, M. and Tree, T. I. M. 2008. Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clinical and Experimental Immunology 154(3), pp. 353-359. (10.1111/j.1365-2249.2008.03810.x)
• Searle, A. et al. 2008. Reducing the burden of chronic wounds: prevention and management of the diabetic foot in the context of clinical guidelines. Journal of Health Services Research and Policy 13(Supp 3), pp. 82-91. (10.1258/jhsrp.2008.008011)
• Searle, A., Wetherell, M. A., Campbell, R., Dayan, C. M., Weinman, J. and Vedhara, K. 2008. Do patients’ beliefs about type 2 diabetes differ in accordance with complications: An investigation into diabetic foot ulceration and retinopathy. International Journal of Behavioral Medicine 15(3), pp. 173-179. (10.1080/10705500802212940)

2007

• Jun-Fen, F., Chun-Lin, W., Li, L., Dayan, C. M., Guan-Ping, D. and Fang, H. 2007. Kikuchi-Fujimoto disease manifesting as recurrent thrombocytopenia and Mobitz type II atrioventricular block in a 7-year-old girl: a case report and analysis of 138 Chinese childhood Kikuchi-Fujimoto cases with 10 years of follow-up in 97 patients [review]. Acta Paediatrica 96(12), pp. 1844-1847. (10.1111/j.1651-2227.2007.00523.x)
• Williams, A. J. K., Chau, W., Callaway, M. P. and Dayan, C. M. 2007. Magnetic resonance imaging: a reliable method for measuring pancreatic volume in Type 1 diabetes. Diabetic Medicine 24(1), pp. 35-40. (10.1111/j.1464-5491.2007.02027.x)
• Baker, C. et al. 2007. Activated T cell subsets in human type 1 diabetes: evidence for expansion of the DR+ CD30+ subpopulation in new-onset disease. Clinical and Experimental Immunology 147(3), pp. 472-482. (10.1111/j.1365-2249.2006.03307.x)
• Saravanan, P., Siddique, H., Simmons, D., Greenwood, R. and Dayan, C. M. 2007. Twenty-four hour hormone profiles of TSH, free T3 and free T4 in hypothyroid patients on combined T3/T4 therapy. Experimental and Clinical Endocrinology & Diabetes 115(4), pp. 261-267. (10.1055/s-2007-973071)
• Dayan, C. M. and Dayan, M. R. 2007. Dysthyroid optic neuropathy: a clinical diagnosis or a definable entity?. British Journal of Ophthalmology 91(4), pp. 409-410. (10.1136/bjo.2006.110932)
• Lee, R. W. J., Creed, T. J., Schewitz, L. P., Newcomb, P. V., Nicholson, L. B., Dick, A. D. and Dayan, C. M. 2007. CD4+CD25int T cells in inflammatory diseases refractory to treatment with glucocorticoids. The Journal of Immunology 179(11), pp. 7941-7948. (10.4049/jimmunol.179.11.7941)

2006

• Fu, J. F., Dong, G. P., Liang, L., Jiang, Y. J., Chen, L. Q. and Dayan, C. M. 2006. Early activation of the inhibin B/FSH axis in obese Tanner stage G1PH1 boys. Clinical Endocrinology -Oxford- 65(3), pp. 327-332. (10.1111/j.1365-2265.2006.02597.x)
• Saravanan, P., Visser, T. J. and Dayan, C. M. 2006. Psychological well-being correlates with free thyroxine but not free 3,5,3′-triiodothyronine levels in patients on thyroid hormone replacement. Journal of Clinical Endocrinology & Metabolism 91(9), pp. 3389-3392. (10.1210/jc.2006-0414)
• Creed, T. J., Probert, C. S. J., Norman, M. N., Moorghen, M., Shepherd, N. A., Hearing, S. D. and Dayan, C. M. 2006. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Alimentary Pharmacology and Therapeutics 23(10), pp. 1435-1442. (10.1111/j.1365-2036.2006.02904.x)

2005

• Saravanan, P., Simmons, D. J., Greenwood, R., Peters, T. J. and Dayan, C. M. 2005. Partial substitution of Thyroxine (T4) with Tri-Iodothyronine in patients on T4Replacement therapy: results of a large community-based randomized controlled trial. Journal of Clinical Endocrinology & Metabolism 90(2), pp. 805-812. (10.1210/jc.2004-1672)

2004

• Arif, S. et al. 2004. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. The Journal of Clinical Investigation 113(3), pp. 451-463. (10.1172/JCI19585)
• Narendran, P., Elsegood, K., Leech, N. J., Macindoe, W. M., Boons, G. and Dayan, C. M. 2004. Dendritic cell-based assays, but not mannosylation of antigen, improves detection of T-cell responses to proinsulin in type 1 diabetes. Immunology 111(4), pp. 422-429. (10.1111/j.1365-2567.2004.01825.x)
• Lindley, S., Dayan, C. M., Bishop, A., Roep, B. O., Peakman, M. and Tree, T. I. M. 2004. Defective suppressor function in CD4+CD25+ T-cells from patients with type 1 diabetes. Diabetes 54(1), pp. 92-99. (10.2337/diabetes.54.1.92)

2003

• Finucane, K., Ambrey, P., Narayan, S., Archer, C. B. and Dayan, C. M. 2003. Insulin injection abscesses caused by Mycobacterium chelonae [letter]. Diabetes Care 26(8), pp. 2483-2484. (10.2337/diacare.26.8.2483)
• Dayan, C. M. 2003. Misconceptions in thyroid eye disease. Practitioner 247(1648), pp. 576-580.
• Narendran, P., Williams, A. J., Elsegood, K., Leech, N. J. and Dayan, C. M. 2003. Humoral and cellular immune responses to proinsulin in adults with newly diagnosed type 1 diabetes. Diabetes/Metabolism Research and Reviews 19(1), pp. 52-59. (10.1002/dmrr.332)
• Creed, T. J. et al. 2003. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Alimentary Pharmacology and Therapeutics 18(1), pp. 65-75. (10.1046/j.1365-2036.2003.01639.x)
• Dayan, C. M. 2003. Human monoclonal thyroid-stimulating autoantibody: how useful is a holy grail?. The Lancet 362(9378), pp. 92-93. (10.1016/S0140-6736(03)13893-7)
• Baker, C., Richards, L. J., Dayan, C. M. and Jessop, D. S. 2003. Corticotropin-releasing hormone immunoreactivity in human T and B cells and macrophages: colocalization with arginine vasopressin. Journal of Neuroendocrinology 15(11), pp. 1070-1074. (10.1046/j.1365-2826.2003.01099.x)

2002

• Dayan, C. M., Saravanan, P. and Bayly, G. 2002. Whose normal thyroid function is better—yours or mine?. The Lancet 360(9330), pp. 353-354. (10.1016/S0140-6736(02)09602-2)
• Varela-Calvino, R., Ellis, R., Sgarbi, G., Dayan, C. M. and Peakman, M. 2002. Characterization of the T-cell response to coxsackievirus B4: evidence that effector memory cells predominate in patients with type 1 diabetes. Diabetes 51(6), pp. 1745-1753. (10.2337/diabetes.51.6.1745)
• Lambert, A. P., Hunt, M. A., Day, A. P., Bayly, G. R. and Dayan, C. M. 2002. Reproducibility of individualized coronary heart disease risk calculations in patients with diabetes mellitus. Diabetic Medicine 19(6), pp. 514-517. (10.1046/j.1464-5491.2002.00687.x)
• Saravanan, P., Chau, W., Roberts, N., Vedhara, K., Greenwood, R. and Dayan, C. M. 2002. Psychological well-being in patients on ‘adequate’ doses of l-thyroxine: results of a large, controlled community-based questionnaire study. Clinical Endocrinology 57(5), pp. 577-585. (10.1046/j.1365-2265.2002.01654.x)
• Dayan, C. M. and Lightman, S. A. 2002. Pharmacotherapeutics and the endocrine system: blocking, replacing and exploiting nature's magic bullets. Current Opinion in Pharmacology 2(6), pp. 691-693. (10.1016/S1471-4892(02)00223-0)

2001

• Dayan, C. M. 2001. Stressful life events and Graves' disease revisited [editorial]. Clinical Endocrinology 55(1), pp. 13-14. (10.1046/j.1365-2265.2001.01289.x)
• Saravanan, P. and Dayan, C. M. 2001. Thyroid autoantibodies [review]. Endocrinology and Metabolism Clinics of North America 30(2), pp. 315-337.
• Dayan, C. M. 2001. Interpretation of thyroid function tests. The Lancet 357(9256), pp. 619-624. (10.1016/S0140-6736(00)04060-5)
• Peakman, M. and Dayan, C. M. 2001. Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire?. Immunology 104(4), pp. 361-366. (10.1046/j.1365-2567.2001.01335.x)
• Varela-Calvino, R., Sgarbi, G., Wedderburn, L. R., Dayan, C. M., Tremble, J. and Peakman, M. 2001. T Cell activation by coxsackievirus B4 antigens in type 1 diabetes mellitus: evidence for selective TCR V  usage without superantigenic activity. The Journal of Immunology 167(6), pp. 3513-3520. (10.4049/jimmunol.167.6.3513)

2000

• Walsh, J. P. and Dayan, C. M. 2000. Role of biochemical assessment in management of corticosteroid withdrawal [review]. Annals of Clinical Biochemistry 37(3), pp. 279-288. (10.1258/0004563001899410)
• Hearing, S. D., Probert, C., Norman, M. and Dayan, C. M. 2000. Lymphocyte steroid sensitivity (LSS) in remission and outcome of steroid therapy for severe ulcerative colitis (UC). Gastroenterology 118(4), pp. A791. (10.1016/s0016-5085(00)85306-8)
• Maile, R., Elsegood, K. A., Harding, T. C., Uney, J. B., Stewart, C. E., Banting, G. and Dayan, C. M. 2000. Effective formation of major histocompatibility complex class II-peptide complexes from endogenous antigen by thyroid epithelial cells. Immunology 99(3), pp. 367-374. (10.1046/j.1365-2567.2000.00958.x)

1999

• Hearing, S. D., Norman, M., Smyth, C., Foy, C. and Dayan, C. M. 1999. Wide variation in lymphocyte steroid sensitivity among healthy human volunteera. Journal of Clinical Endocrinology and Metabolism 84(11), pp. 4149-4154. (10.1210/jc.84.11.4149)
• Ahlquist, J., Walsh, J. P. and Dayan, C. M. 1999. Radioiodine and thyroid eye disease - Reply. BMJ 319(7217), pp. 1133-1133. (10.1136/bmj.319.7217.1133a)
• Hearing, S. D., Norman, M., Probert, C. S., Haslam, N. and Dayan, C. M. 1999. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut 45(3), pp. 382-388. (10.1136/gut.45.3.382)
• Walsh, J. P., Dayan, C. M. and Potts, M. J. 1999. Radioiodine and thyroid eye disease - Use with caution. BMJ 319(7202), pp. 68-69. (10.1136/bmj.319.7202.68)
• Hearing, S. D., Norman, M. and Dayan, C. M. 1999. In vitro measurement of lymphocyte steroid sensitivity: lack of agreement between whole blood culture and separated lymphocyte culture. Immunopharmacology and Immunotoxicology 21(1), pp. 41-53. (10.3109/08923979909016393)

1998

• Leech, N. J. and Dayan, C. M. 1998. Controversies in the management of Graves' disease [review]. Clinical Endocrinology -Oxford- 49(3), pp. 273-280. (10.1046/j.1365-2265.1998.00558.x)

1997

• Jessop, D. S., Douthwaite, J. A., Conde, G. L., Lightman, S. L., Dayan, C. M. and Harbuz, M. S. 1997. Effects of Acute Stress or Centrally Injected Interleukin-1beta on Neuropeptide Expression in the Immune System. Stress -Basel- 2(2), pp. 133-144. (10.3109/10253899709014744)
• Jessop, D. S., Harbuz, M. S., Snelson, C. L., Dayan, C. M. and Lightman, S. L. 1997. An antisense oligodeoxynucleotide complementary to corticotropin-releasing hormone mRNA inhibits rat splenocyte proliferation in vitro. Journal of Neuroimmunology 75(1-2), pp. 135-140. (10.1016/s0165-5728(97)00011-8)
• Dayan, C. M., Elsegood, K. A. and Maile, R. 1997. FasL expression on epithelial cells: the Bottazzo-Feldman hypothesis revisited [review]. Immunology Today 18(5), pp. 203. (10.1016/s0167-5699(97)81661-1)
• Maile, R., Elsegood, K. A. and Dayan, C. M. 1997. Functionality of inducible major histocompatibility class II expression by specialised non-lymphoid cells. Biochemical Society Transactions 25(2), pp. 318S.

1996

• Dayan, C. M. and Daniels, G. 1996. Chronic autoimmune thyroiditis [review]. New England Journal of Medicine 335(2), pp. 99-107. (10.1056/nejm199610033351425)
• Dayan, C. M. et al. 1996. Biochemical cure of recurrent acromegaly by resection of cervical spinal canal metastases. Clinical Endocrinology -Oxford- 44(5), pp. 597-602. (10.1046/j.1365-2265.1996.685507.x)
• Quaratino, S., Feldmann, M., Dayan, C. M., Acuto, O. and Londei, M. 1996. Human self-reactive T cell clones expressing identical T cell receptor beta chains differ in their ability to recognize a cryptic self-epitope. Journal of Experimental Medicine 183(2), pp. 349-358. (10.1084/jem.183.2.349)

1995

• Dayan, C. M. and Jackson, M. 1995. The 1995 Advanced Medicine Conference [congress]. Clinical Medicine - London 29(4), pp. 344-348.
• Mullins, R. J., Cohen, S. B., Webb, L. M., Chernajovsky, Y., Dayan, C. M., Londei, M. and Feldmann, M. 1995. Identification of thyroid stimulating hormone receptor-specific T cells in Graves' disease thyroid using autoantigen-transfected Epstein-Barr virus-transformed B cell lines. The Journal of Clinical Investigation 96(1), pp. 30-37. (10.1172/jci118034)
• Wong, N. A., Dayan, C. M., Virjee, J. and Heaton, K. W. 1995. Acute respiratory distress secondary to Morgagni diaphragmatic herniation in an adult. Postgraduate Medical Journal -London- 71(831), pp. 39-41. (10.1136/pgmj.71.831.39)

1994

• Mullins, R. J., Chernajovsky, Y., Dayan, C. M., Londei, M. and Feldmann, M. 1994. Transfection of thyroid autoantigens into EBV-transformed B cell lines. recognition by Graves' disease thyroid T cells. The Journal of Immunology 152(11), pp. 5572-5580.

1993

• Dayan, C. M., Chu, N. R., Londei, M., Rapoport, B. and Feldmann, M. 1993. T cells involved in human autoimmune disease are resistant to tolerance induction. The Journal of Immunology 151(3), pp. 1606-1613.
• Dayan, C. M. 1993. Provider power: an important lesson from the US health care market. Clinical Medicine 27(3), pp. 238-241.
• Lehmann, P. V., Sercarz, E. E., Forsthuber, T., Dayan, C. . M. and Gammon, G. 1993. Determinant spreading and the dynamics of the autoimmune T-cell repertoire [review]. Immunology Today 14(5), pp. 203-208. (10.1016/0167-5699(93)90163-f)
• Quaratino, S., Dayan, C. M., Feldmann, M. and Londei, M. 1993. Definition of the tri-molecular complex of human thyroid peroxidase specific autoreactive t-cell clones. Journal of Cellular Biochemistry 17(Supp C), pp. 72-72.

1992

• Feldmann, M., Dayan, C. M., Grubeck-loebenstein, B., Rapoport, B. and Londei, M. 1992. Mechanism of Graves thyroiditis: implications for concepts and therapy of autoimmunity [Review]. International Reviews of Immunology 9(2), pp. 91-106. (10.3109/08830189209061785)
• Dayan, C. M., Feldmann, M., Rapoport, B. and Londei, M. 1992. Autoimmune thyroiditis and targeted anti-T cell immunotherapy in man [review]. Autoimmunity 11(3), pp. 189-198. (10.3109/08916939209035154)

1991

• Dayan, C. M., Londei, M., Corcoran, A., Grubeck-Loebenstein, B., James, R. F., Rapoport, B. and Feldmann, M. 1991. Autoantigen recognition by thyroid-infiltrating T cells in Graves disease. Proceedings of the National Academy of Sciences of the United States of America 88(16), pp. 7415-7419. (10.1073/pnas.88.16.7415)

1990

• Zheng, R. Q., Abney, E. R., Grubeck-Loebenstein, B., Dayan, C. M., Maini, R. N. and Fledmann, M. 1990. Expression of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-3 on human thyroid epithelial cells in Graves' and Hashimoto's diseases. Journal of Autoimmunity 3(6), pp. 727-736. (10.1016/s0896-8411(05)80039-3)